We have previously shown that loss of heterozygosity (LOH) on human chromosome (hchr) 7 at q31.1 is common in a variety of tumors of epithelial origin. Frequent LOH of a speci®c chromosomal marker is indicative of a closely linked tumor suppressor gene (TSG). However, recent reports have also indicated that such a high frequency of LOH could be due to the presence in this region of the second most common aphidicolin-inducible fragile site in the human genome (Fra7G). To address this controversy, we introduced single copies of hchr7 or hchr12 into a highly aggressive human prostate carcinoma cell line (PC3) by microcellmediated transfer. The tumorigenicity of six clones of PC3/hchr7 hybrids and three clones of PCRhchr12 hybrids, obtained in four separate fusion experiments, were studied in BALB/c nude mice. All but one of the PC3/hchr7 hybrids increased tumor latency by at least twofold, whereas none of the PC3/hchr12 hybrids delayed tumor onset. No dierences in the in vitro growth rate were observed among any of the cell lines assayed (parental and hybrids) suggesting that the observed tumor suppression was due to factors other than cell cycle regulation. Deletion mapping of the PC3/ hchr7 tumors obtained after reversion to the malignant phenotype revealed a common region of loss centred around 7q31.1, supporting the TSG hypothesis. The smallest commonly deleted region was *1.5 Mb in size and¯anked by the markers D7S486 and D7S655.
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Keywords: human chromosome 7; prostate carcinoma; tumor suppressor gene; microcell fusion; tumorigenesis Frequent loss of heterozygosity (LOH) of a speci®c chromosomal marker is considered an indication of a closely linked tumor suppressor gene (TSG) (Gupta et al., 1997) . Deletions in 7q in a variety of human neoplasias have been reported on numerous occasions over the past decade (Zenklusen and Conti, 1996) . Reports of frequent LOH of markers on human chromosome (hchr) 7q in breast carcinomas (Bieche et al., 1992; Zenklusen et al., 1994a) , malignant myeloid disorders (Newman et al., 1992) , prostate carcinomas (Zenklusen et al., 1994b; Oakahashi et al., 1995; Cunningham et al., 1996) , ovarian carcinomas (Zenklusen et al., 1995a; Koike et al., 1997) , colon carcinomas (Zenklusen et al., 1995b) , head and neck carcinomas (HNSCC) (Zenklusen et al., 1995b) , gastric carcinomas (Nishizuka et al., 1997; Kuniyasu et al., 1996) , pancreatic carcinomas (Achille et al., 1996) , and renal cell carcinomas (Shridhar et al., 1997) strongly suggest that a putative TSG resides in 7q31.1-q31.2.
Recent studies by Smith (Huang et al., 1998a,b) have located the second most common aphidicolin-inducible fragile site in the human genome (Fra7G) to this same region of chromosome 7. The presence of such a site suggests an alternate explanation for the frequent LOH in the region, namely, that the allelic imbalance re¯ects intrinsic genomic instability of the region rather than targeted disruption of a TSG. Note that this hypothesis does not preclude the simultaneous co-existence of both a fragile site and a TSG in the same region, as is the case with the Fragile Histidine Triad gene (FHIT, a known TSG) and the Fra3B site (Huebner et al., 1997) .
Microcell-mediated chromosome transfer procedures can be used for introducing speci®c chromosomes into cell lines derived from human tumors to test for suppression of the tumorigenic phenotype (Sanchez et al., 1996; Ewing et al., 1995) . Functional assays have demonstrated that the introduction of an intact copy of hchr7 can restore senescence to immortalized human ®broblast cell lines having LOH at 7q31-q32 (Ogata et al., 1993) and can inhibit the tumorigenic phenotype of a murine-derived squamous cell carcinoma cell line (Zenklusen et al., 1994c) . Recently, introduction of hchr7 into a choriocarcinoma cell line delayed tumorigenicity of the microcell hybrids (Matsuda et al., 1997) . However, the critical region of LOH in the latter type of tumor is typically 7p12-q11.3, suggesting an additional TSG may be present on hchr7 that is relevant to the tumorigenesis of a dierent group of neoplasias, as previously suggested (Zenklusen and Conti, 1996) . While LOH studies suggest the presence of a TSG on 7q31.1-31.2, there has to date been no direct evidence that insertion of this genomic region represses the tumorigenicity of human epithelial neoplasia-derived cell lines.
Due to the properties of the recipient cells, microcell fusion hybrids tend to be genetically unstable once inoculated into nude mice. Depending on the tumorigenic potential of the parental cell line, the repressed hybrids often revert to the tumorigenic phenotype within the course of the ®rst (Zenklusen et al., 1994c) or several of animal passages (Szeles et al., 1997) . Deletion mapping of such revertants by means of microsatellite analysis and/or¯uorescence in situ hybridization frequently reveals total (Zenklusen et al., 1994c) or partial deletion (Szeles et al., 1997; Cheng et al., 1998) of the introduced chromosome. Partial deletions can occur through mitotic recombination (Gupta et al., 1997) , thereby recapitulating the genetic history of the tumors. Elucidating the overlap of such allelic imbalances in a series of revertants can help to pinpoint the location of putative TSG in a fashion analogous to LOH studies in unrelated primary neoplasias (Szeles et al., 1997; Cheng et al., 1998) .
For our studies, we investigated the ability of neotagged hchr7 and hchr12 to suppress the malignant phenotype of PC3 cells (an androgen-independent human prostate adenocarcinoma cell line) (Kaighn et al., 1978) in nude mice. We selected PC3 as our target cell line because of its extensive hemizygosity at 7q31, which indicates a high probability of LOH in the region. Since normal DNA from the patient from whom PC3 was derived is not available, conventional LOH studies cannot be performed. As a substitute, we employed an alternative method called homozygosity mapping of deletions (HOMOD) (JW Fountain, personal communication). Speci®cally, we ampli®ed microsatellite-based genetic markers from the region of hchr7 where LOH is common in prostate carcinoma (Zenklusen et al., 1994b; Oakahashi et al., 1995; Cunningham et al., 1996) , in each case assessing the number of alleles present in PC3 cells. The selected genetic markers are highly polymorphic, making very small the probability that ®ve or more adjacent markers would be homozygous by chance. We found eight consecutive genetic markers (D7S523-D7S486 -D7S522 -D7S2430 -D7S633 -D7S677 -D7S655-D7S480) (Weissenbach et al., 1992) to be homozygous in PC3 cells (Figure 1a) . There is only a 1/10 000 probability of this occurring randomly, suggesting that this heterozygosity is due to a recombination event on one of the hchr7 homologs, leading to the inactivation of a TSG in the region.
Six microcell hybrids of PCR3 containing hchr7 (PC3721, PC3722, PC3723, PC3724, PC3725, and PC3726) were obtained and used for tumorigenicity studies. Parental PC3 cells (26), and three PC3/hchr12 hybrids (PC31222, PC31223, and PC31225) were used as controls.
To con®rm the presence of the introduced hchr in the hybrid cell lines, we performed PCR to detect the neo marker and genetic markers within the deleted region of 7q31 ( Figure 1b) . As suggested by their ability to grow in G418, all hybrids were positive for the neo marker, indicating that a tagged hchr was present. Moreover, for some of the genetic markers PCR ampli®cation of the neo marker in the donor, parental, and hybrid cell lines. L, ladder; 7Neo, A9 murine cell line with a neotagged hchr7; 12Neo, A9 murine cell line with a neo-tagged hchr12; PC3721, PC3722, PC3723, PC3724, PC3725, and PC3726, PC3/hchr7 hybrids; PC31222, PC31223, and PC31225, PC3/ hchr12 hybrids; PC3, parental invasive prostate adenocarcinoma cell line. (c) PCR ampli®cation of representative microsatellite markers in the donor, parental, and hybrid cell lines Figure 2 The in vitro growth ability of the microcell fusion was assayed by plating 2610 3 cells/well in 24-well plates. Fifteen identical plates were then incubated at 378C, being ®xed at regularly spaced intervals in freshly prepared 3 : 1 methanol:acetic acid and then stained with a 2% Eriochrome Black T solution in 50% ethanol for 10 min. Images of the stained plates were captured with an AlphaImager 2000 documentation and analysis system (Alpha Inotech Corp., San Leandro, CA, USA) and the optical density of each well was determined using the array analysis software. Top: PC3/hchr7 hybrids. Bottom: PC3/hchr12 hybrids (D7S677 and D7S655) homozygous in the parental cell line, an addition allele was detected in the hybrids that matched the one in the donor cell line (7neo), indicating the presence of the transferred hchr7 ( Figure  1c) . Figure 2 shows the in vitro growth curves of PC3 and the microcell hybrids. There was no correlation between the ability of the cells to proliferate in vitro and their in vivo tumorigenic growth. Speci®cally, the PC3/hchr12 hybrids (which had the highest tumorigenicity, see below) showed moderate proliferative behavior in vitro, whereas the non-tumorigenic PC3/ hchr7 hybrids grew at roughly the same rate as the parental PC3 cells. These data demonstrate that the transfer of a hchr7 into PC3 cells does not alter their in vitro proliferative ability; suggesting that the mechanism of action of the putative hchr7 TSG involves a cell-cell or cell-environment interaction rather than regulation of the cell-cycle machinery. Thus, the TSG on hchr7 may act within a progression pathway (e.g., angiogenesis, extracellular matrix remodeling) as opposed to the initiation stage of the tumor. However, we cannot rule out that the putative TSG on 7 may act in collaboration with an environmental signal in vivo to regulate proliferation, and that this eect is not evident in cell culture due to the lack of this cofactor.
To assess the tumorigenic potential of the microcell hybrids, tumor growth curves were constructed based on three independent experiments in which every cell line was injected subcutaneously into BALB/c nude mice. The data for the cell lines from each of the three experiments were plotted, and the three resulting curves were compared by ANCOVA analysis followed by a Tukey's test (Zar, 1996) . As there were not signi®cant dierences among the curves, all the data from the injections for a given hybrid were plotted in a single curve (Figure 3) . Figure 3 shows the changes in total tumor mass for each cell line as a function of time after injection into the backs of male mice. All the PC3/hchr12 hybrids yielded total tumor loads and latency period similar to the parental cell line (P50.2). This con®rmed that introduction of a human chromosome per se into PC3 cells followed by clonal selection did not abrogate tumorigenicity. On the other hand, ®ve of six PC3/ hchr7 hybrids resulted in signi®cantly longer latency periods and smaller tumor masses than the parental PC3 cells and the control hybrids. The latency of the PC3726 hybrid was less than 50% longer than that of the PC3 cells, but its tumor load was less than 25% of that obtained with the control cells. No gross deletion was found in the transferred hchr7 within PC3726 by PCR analysis, and histological analysis of the tumor revealed poorly dierentiated adenocarcinomas (as with the tumors obtained from repressed hybrids and the parental cell line). Figure 3 In vivo tumorigenicity curves of PC3 hybrids. A total of 120 male BALB/c athymic nude mice were used. Each animal was injected at the age of 4 ± 6 weeks with 1610 6 cells into each of two sites in the lower dorsal region. Tumor growth was followed by diameter measurements twice per week. Total tumor mass was calculated as TTM={(tumor diameter/2) 3 }/total number of sites injected. Top: Microcell-fusion hybrids containing a single hchr7. Note that hybrids PC3721 and PC3725 failed to produce any tumors, thus their curves converged at zero TTM. Hybrids PC3722 and PC3724 also have convergent curves. Bottom: Microcell fusion hybrids containing a single hchr12 Figure 4 Schematic representation of the status of 18 microsatellite markers in six tumors derived from revertants of the repressed PC3/hchr7 hybrids. Tumor numbers are shown along the top. Full bars/circles represent deleted chromosomal fragment/marker for the transferred hchr7. Empty bars/circles represent deleted chromosomal fragment/marker for the transferred hchr7. Smallest commonly deleted region is depicted by the thick bar at the far right ANCOVA followed by Tukey's test (Zar, 1996) analysis of these data revealed two groups of cell lines with statistically dierent latencies (P50.001): one group consisting of the parental PC3 cell line, the hchr12 hybrids PC31222, PC31223, PC31225, and the hchr7 hybrid PC3726, with a second group including the hchr7 hybrids PC3721, PC3722, PC3723, PC3724, and PC3725. When the total tumor mass at 60 days post-injection was used as the discriminating factor, the cell lines again fell into two groups (P50.001): one containing all of the control cell lines (PC3 and PC3/ hchr12 hybrids) and the other including all of the PC3/ hchr7 hybrids (which had signi®cantly lower tumor masses).
Together, our data indicate that hchr7 contains an active TSG capable of abrogating the tumorigenicity of the highly malignant PC3 cells. However, it is also possible that the TSG is located in a region other than q31.1-q31.2, and that the LOH observed in this area is due to the presence of the Fra7G site. For the repressed hybrids to regain the parental tumorigenic phenotype, it would be necessary to inactivate the introduced copy of the hchr7 TSG. This could occur either by deletion of the region containing the TSG or by point mutation of the gene. Since the second option would require a highly speci®c genetic alteration, it is generally thought (Gupta et al., 1997) that deletion of the region by recombination is the most likely event. Thus, the tumors obtained from repressed hybrids after their reversion to a malignant phenotype should contain a deletion in the region harboring the TSG.
We performed extensive deletion analysis of all tumors obtained from the PC3/hchr7 hybrids to delineate which regions (if any) of the exogenous hchr7 were lost during tumorigenic reversion. A series of 18 microsatellite markers distributed across hchr7
were ampli®ed, and the number of alleles were assessed (Figure 4) . The speci®c genetic markers were selected such that the allele on the hchr7 from the 7Neo donor cells diered in size from the endogenous PC3-derived alleles. The most frequent deletion in the 24 tumors studied is the complete loss of hchr 7q. However, in nine tumors, a discrete deletion involving only part of the 7q arm was encountered (Figure 4) . These deletions have a *1.5 Mb (Zenklusen et al., 1999) minimal common region¯anked by D7S486 and D7S655. This commonly deleted segment includes marker D7S522, which has been shown to be frequently deleted in a variety of neoplasias (Zenklusen and Conti, 1996) . This line of evidence con®rms that a TSG capable of abrogating the tumorigenicity of a highly aggressive human prostate carcinoma cell line (PC3) is located on 7q31.1.
The presence of the second most common aphidicolin-inducible fragile site in the human genome (Fra7G) in the same region as the putative TSG may have some important signi®cance. As demonstrated by Croce et al. (Huebner et al., 1997) , fragile sites can be choice locations for TSGs since their instability makes the region prone to alterations that would result in the eective inactivation of these regulatory genes. Screening areas of known fragility may lead to a more methodic discovery of TSGs. Our eorts are now focused on isolating the hchr7 TSG, to this end a detailed physical and expression map of the region has been recently produced (Zenklusen et al., 1999) .
